Review article · 2023 · Open access

TACkling Cancer by Targeting Selective Protein Degradation

María del Mar Noblejas‐López, David Tébar-García, Raquel López‐Rosa, Ana Lucía Alcaraz-Sanabria, Pablo Cristóbal‐Cueto, Alejandro Pinedo‐Serrano, Lorenzo Rivas‐García, Eva María Galán‐Moya

Pharmaceutics, 15(10), 2442 · Published 10 October 2023 · DOI 10.3390/pharmaceutics15102442

Open PDFView at the publisherCite this paper

In brief

“TACkling Cancer by Targeting Selective Protein Degradation” is a 2023 review article by María del Mar Noblejas‐López and 7 co-authors, published in Pharmaceutics. OpenAlex counts 30 citations as of 21 November 2026, which puts it in the top 2% of works published in 2023 by citations. It is open access under a CC BY licence: the full text is free to read at Pharmaceutics.

Citations
30
Most cited in
2025 (16)
Field-weighted impact
0.68
References
89
Authors
8

Abstract

Targeted protein degradation has emerged as an alternative therapy against cancer, offering several advantages over traditional inhibitors. The new degrader drugs provide different therapeutic strategies: they could cross the phospholipid bilayer membrane by the addition of specific moieties to extracellular proteins. On the other hand, they could efficiently improve the degradation process by the generation of a ternary complex structure of an E3 ligase. Herein, we review the current trends in the use of TAC-based technologies (TACnologies), such as PROteolysis TArgeting Chimeras (PROTAC), PHOtochemically TArgeting Chimeras (PHOTAC), CLIck-formed Proteolysis TArgeting Chimeras (CLIPTAC), AUtophagy TArgeting Chimeras (AUTAC), AuTophagosome TEthering Compounds (ATTEC), LYsosome-TArgeting Chimeras (LYTAC), and DeUBiquitinase TArgeting Chimeras (DUBTAC), in experimental development and their progress towards clinical applications.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Noblejas‐López, M. D. M., Tébar-García, D., López‐Rosa, R., Alcaraz-Sanabria, A. L., Cristóbal‐Cueto, P., Pinedo‐Serrano, A., Rivas‐García, L., & Galán‐Moya, E. M. (2023). TACkling Cancer by Targeting Selective Protein Degradation. Pharmaceutics, 15(10), 2442. https://doi.org/10.3390/pharmaceutics15102442

MLA 9

Noblejas‐López, María del Mar, et al. “TACkling Cancer by Targeting Selective Protein Degradation.” Pharmaceutics, vol. 15, no. 10, 2023, p. 2442. https://doi.org/10.3390/pharmaceutics15102442.

Chicago

Noblejas‐López, María del Mar, David Tébar-García, Raquel López‐Rosa, Ana Lucía Alcaraz-Sanabria, Pablo Cristóbal‐Cueto, Alejandro Pinedo‐Serrano, Lorenzo Rivas‐García, and Eva María Galán‐Moya. 2023. “TACkling Cancer by Targeting Selective Protein Degradation.” Pharmaceutics 15 (10): 2442. https://doi.org/10.3390/pharmaceutics15102442.

Harvard

Noblejas‐López, M. D. M. et al. (2023) ‘TACkling Cancer by Targeting Selective Protein Degradation’, Pharmaceutics, 15(10), p. 2442. doi:10.3390/pharmaceutics15102442.

IEEE

M. D. M. Noblejas‐López et al., “TACkling Cancer by Targeting Selective Protein Degradation,” Pharmaceutics, vol. 15, no. 10, p. 2442, 2023, doi: 10.3390/pharmaceutics15102442.

BibTeX

@article{noblejaslopez2023tackling,
  title     = {{TACkling Cancer by Targeting Selective Protein Degradation}},
  author    = {Noblejas‐López, María del Mar and Tébar-García, David and López‐Rosa, Raquel and Alcaraz-Sanabria, Ana Lucía and Cristóbal‐Cueto, Pablo and Pinedo‐Serrano, Alejandro and Rivas‐García, Lorenzo and Galán‐Moya, Eva María},
  journal   = {Pharmaceutics},
  year      = {2023},
  volume    = {15},
  number    = {10},
  pages     = {2442},
  doi       = {10.3390/pharmaceutics15102442},
  url       = {https://doi.org/10.3390/pharmaceutics15102442}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202488
20251616
202666

Its field-weighted citation impact is 0.68: it has been cited 0.68 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors

  • targeted protein degradation
  • PROTACs
  • lysosome-targeting chimeras
  • E3 ubiquitin ligase
  • cancer therapy
  • lysosomal targeting
  • clinical development

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

Noblejas‐López, M. D. M., Tébar-García, D., López‐Rosa, R., Alcaraz-Sanabria, A. L., Cristóbal‐Cueto, P., Pinedo‐Serrano, A., Rivas‐García, L., & Galán‐Moya, E. M. (2023). TACkling Cancer by Targeting Selective Protein Degradation. Pharmaceutics, 15(10), 2442. https://doi.org/10.3390/pharmaceutics15102442

How many times has this paper been cited?

30 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Pharmaceutics: sign in and open the PDF from this page.

Who wrote this paper?

María del Mar Noblejas‐López, David Tébar-García, Raquel López‐Rosa, Ana Lucía Alcaraz-Sanabria, Pablo Cristóbal‐Cueto, Alejandro Pinedo‐Serrano, Lorenzo Rivas‐García, Eva María Galán‐Moya.

What is the DOI of this paper?

10.3390/pharmaceutics15102442, permanently at https://doi.org/10.3390/pharmaceutics15102442. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.